Understanding how acetylation affects HIV infection control
Official title: Role of Factor Acetylation in the Regulation of HIV Transcription
Funded at J. David Gladstone Institutes · NIH-10805634 · Data updated 2026-11-12
This study is looking at how certain proteins help control HIV's ability to hide in the body and how we might find new ways to treat it, which could lead to better options for people living with HIV.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $737,100 |
| NIH project number | 4R37AI083139-15 |
| Project ID | NIH-10805634 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV, particularly those experiencing challenges with viral latency.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research investigates the role of acetylation in the regulation of HIV transcription, focusing on how certain proteins interact with acetyl-lysine residues to influence HIV latency. By exploring the mechanisms behind latency establishment, maintenance, and reactivation, the study aims to identify potential drug targets that could lead to effective treatments for HIV. The approach includes a series of experiments designed to test the interactions between various proteins and their effects on HIV gene expression. Patients may benefit from advancements in treatment strategies that could arise from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that effectively control or eliminate latent HIV infections.
How similar studies have gone: Previous research has shown promise in targeting acetylation pathways in other viral infections, suggesting potential for success in this novel approach to HIV.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Ott, Melanie Maria — J. David Gladstone Institutes
- Study coordinator: Ott, Melanie Maria
Related research
Other NIH-funded projects on the same topics.
-
HOPE: a new approach to silencing HIV and preventing rebound
A large NIH grant is testing a combination strategy to turn off HIV genes in people on treatment so the virus stays gone and health improves.
-
Undo HIV: Understanding and targeting the active HIV reservoir
Aims to map and ultimately eliminate the HIV cells that stay active despite therapy to improve long-term control of HIV in people living with HIV.
-
TREM2 and TYROBP in Alzheimer's brain network changes
This grant looks at how microglial proteins TREM2 and TYROBP influence brain network excitability in people with Alzheimer's disease and related dementias.
-
Commensal respiratory viruses and how they interact with the human airway
A small NIH grant is exploring how the normal viruses living in our airways interact with our cells to stay harmless and support healthy breathing.
-
Targeted delivery systems to edit blood stem cells
Aims to safely deliver genome-editing tools to blood stem cells to treat diseases like acute myeloid leukemia.
-
Regionally Specific Transplants to Restore Breathing After Cervical Spine Injury
A patient-focused look at a study that aims to repair breathing circuits after cervical spinal cord injury using stem-cell–derived nerve cells and targeted neuromodulation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.